AIT Therapeutics Names Stephen J. DiPalma as Chief Financial Officer

World News: . []

NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Stephen J. DiPalma of Danforth Advisors, a financial consultancy specialized in working with life sciences companies, will be assuming responsibilities as Chief Financial Officer.  Hai Aviv will remain as AIT’s CFO through April in order to ensure a smooth transition to Mr. DiPalma. 

“I am delighted to welcome Steve to the AIT team.  I also want to thank Hai for his outstanding service to AIT over the past 15 months and wish him well in his future endeavors,” said Steven Lisi, Chairman and Chief Executive Officer of AIT Therapeutics.  “Steve is a tremendous addition for our Company.  He joins us with over 30 years of experience in life sciences and healthcare, including having served as Chief Financial Officer for a number of public and private companies. He brings the experience and insight necessary to help guide AIT as we progress to our next stages of growth.”

Mr. DiPalma said, “I am thrilled to have the opportunity to work closely with the Company’s  seasoned management team.  AIT is on the cusp of transforming the treatment of patients with respiratory conditions with their NO generator and delivery system that will be a substantial benefit for hospitals and patients.  I look forward to being part of that effort.”

As a Managing Director at Danforth Advisors, Mr. DiPalma provides financial, operational and strategic counsel to life science companies and has served as interim CFO to several public and emerging companies in various stages of development, from seed financing through IPO, M&A transactions and for ongoing public companies.  His experience in life sciences and healthcare includes founding two start-ups and working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies.  Prior to Danforth, Mr. DiPalma was the CFO at Forum Pharmaceuticals and was CFO and Executive Vice President of Business Operations at RXi Pharmaceuticals.  Mr. DiPalma’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions.  He holds a BS from the University of Massachusetts and MBA from Babson College.

Bob Yedid LifeSci Advisors, LLC Bob@LifeSciAdvisors.com(646) 597-698 

More news and information about AIT Therapeutics, Inc.

Published By:

Globe Newswire: 13:30 GMT Monday 16th April 2018

Published: .

Search for other references to "therapeutics" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers